Precision BioSciences to Participate in Upcoming June Investor Conferences
May 30 2024 - 6:00AM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene
editing company utilizing its novel proprietary ARCUS® platform to
develop in vivo gene editing therapies for sophisticated gene
edits, including gene elimination, insertion, and excision, today
announced that members of management will participate in the
following upcoming investor conferences in June:
Jefferies Global Healthcare Conference Date: Wednesday,
June 5, 2024 Time: 1:30 pm – 1:55 pm ET Format: Fireside Chat
Webcast Registration: Link
Goldman Sachs 45th Annual Global Healthcare Conference
2024 Date: Wednesday, June 12, 2024 Time: 10:00 am – 10:35 am
ET Format: Fireside Chat Webcast Registration: Link
A live webcast of each presentation will also be accessible on
Precision’s website in the Investors section under Events &
Presentations at investor.precisionbiosciences.com. An archived
replay of the webcasts will be available for approximately 30 days
following each event.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company
dedicated to improving life (DTIL) with its novel and proprietary
ARCUS® genome editing platform that differs from other technologies
in the way it cuts, its smaller size, and its simpler structure.
Key capabilities and differentiating characteristics may enable
ARCUS nucleases to drive more intended, defined therapeutic
outcomes. Using ARCUS, the Company’s pipeline is comprised of in
vivo gene editing candidates designed to deliver lasting cures for
the broadest range of genetic and infectious diseases where no
adequate treatments exist. For more information about Precision
BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene
editing therapies for sophisticated gene edits, including gene
insertion (inserting DNA into gene to cause expression/add
function), elimination (removing a genome e.g. viral DNA or mutant
mitochondrial DNA), and excision (removing a large portion of a
defective gene by delivering two ARCUS nucleases in a single
AAV).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240530614904/en/
Investor and Media Contact: Naresh Tanna Vice President
of Investor Relations naresh.tanna@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Sep 2023 to Sep 2024